These novel medications , Tirzepatide , represent a groundbreaking advancement in treating obesity and potentially other ailments . They all are categorized as GLP-1 pathway agonists , meaning they function to emulate the endogenous GLP-1 peptide, boosting glucose release and lowering appetite . Although Semaglutide every works somewhat similarly,